Zentalis Pharmaceuticals enters its May 14 earnings report with short sellers meaningfully more active than they were a month ago — and options traders signalling the opposite of fear.
Short interest has climbed sharply over the past month. At 8.4% of free float, it is up nearly 39% versus 30 days ago, as measured by shares short. The daily history makes the acceleration clear: positions roughly doubled between mid-April and early May, rising from around 3.2 million shares to over 6 million. Days to cover stands near 3.9, meaning a meaningful short position relative to average volume. Yet the lending market tells a calmer story — availability remains ample and cost to borrow is running well below 1%, near 0.49%, with the borrow market nowhere near stressed despite the increase in short demand.
Options positioning cuts against the bearish short-interest narrative. The put/call ratio has collapsed to just 0.07, the lowest in at least a year and well below its 20-day average of 0.11. That's an unusually call-heavy posture heading into a binary event — options traders are leaning bullish, or at minimum, are not hedging for downside in any meaningful way. The recent price action adds colour: the stock has bounced 4.6% over the past week and 3.4% on Tuesday alone, recovering modestly from a brutal month that saw it fall 35% to $4.28.
The analyst debate centres on whether Zentalis has enough in the pipeline to justify any premium above cash value. Guggenheim raised its price target sharply to $10 from $6 in early April, maintaining its Buy and citing pipeline optionality — a notable move on conviction at a price more than double the current level. Morgan Stanley sits at the opposite end with an Equal-Weight and a $4 target (set in late 2025), essentially pricing the stock at liquidation. The mean target across covering analysts is $6.25, implying meaningful upside on paper — though the wide dispersion between the most optimistic and most sceptical views signals genuine uncertainty about clinical prospects rather than a consensus story. Valuation multiples are uninformative for a pre-profit biotech at this stage; the P/B of 2.4x is the only positive ratio in the set.
Earnings history adds another layer of unpredictability. The four most recent releases produced daily moves of –17.6%, +13.5%, –0.7%, and +9.4% — a wide distribution with no consistent direction. The print will test whether the pipeline update that drove Guggenheim's conviction is something the broader market has yet to price in, or whether the steady accumulation of short interest over the past four weeks reflects a better-informed read on what's coming.
See the live data behind this article on ORTEX.
Open ZNTL on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
